Plain English summary
Introduction
Methods
Study design
Search strategy
Selection criteria
-
Inclusion criteria: Original clinical studies (a) reporting the use of one or more PROMIS measures; (b) including patients with RA and/or axSpA aged 18 years or above; (c) written in English, French, German or Dutch.
-
Exclusion criteria: Studies including patients with multiple diagnoses, but not reporting the information on RA or axSpA patients separately.
Selection process
Data extraction
Results
Study | Country | 1 CS 2 LC 3 RCT 4 Other | 1 RA 2 axSpA | N | Female (%) | Population | Age Mean (SD) | Years since diagnosis mean (SD) | General measures | PROMIS measures of a specific domain | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GH | P-29 | Physical function | Fatigue | Pain IF | Pain BH | Pain IT | Sleep Disturbance/Sleep-Related Impairment | Satisfaction with Social Roles and Activities | APS | Anxiety /anger | Depression | SEMS | |||||||||
Gavigan et al. 2022 [55] | USA | 2 | 2 | 195 | 87.0 | Registry: Arthritis Power Registry | 47.6(10.6) | 38.6(11.2)a | × | × | × | ||||||||||
Becker et al. 2021 [16] | USA | 1 | 1 | 20 12 | 65.0 67.0 | Community: used Pain interference Community: used Sleep Disturbance | 53.2 (11.4) 55.0 (8.5) | 9.2 (7.4) 13.3 (12.0) | × | × | |||||||||||
Bingham et al. 2021 [17] | USA | 2 | 1 | 11 | 91.0 | Clinic: Johns Hopkins Arthritis Centre | 55.0 (12.0) | 20.0 (10.0) | × | × | |||||||||||
Cano-García et al. 2021e [18] | SP | 1 | 1 2 | 50 51 | 90.0 51.0 | Clinic: RA patients Clinic: axSpA patients | 55.1 (13.6) 52.5 (12.1) | 14.3 (7.1) 13.0 (6.1) | × | ||||||||||||
Lee et al. 2021 [19] | USA | 2 | 1 | 3949 | 83.0 | Registry: The National Databank for Rheumatic Diseases (FORWARD) registry | 65.4 (11.9) | 21.7 (12.6) | × | ||||||||||||
USA | 2 | 1 | 196 262 | 81.0 82.0 | Clinic: Johns Hopkins Arthritis Centre Clinics: Johns Hopkins, The Hospital for Special Surgery, University of Alabama | 54.8 (13.4) 56.6 (13.9) | 11.0 (10.0) 13.2 (11.4) | × | × | × | × | × | × | × | |||||||
Gavigan et al. 2020 [23] | USA | 1 | 1 | 249 | 92.0 | Registry: Arthritis Power Registry | 51.7 (11.0) | 11.0 (9.5) | × | × | × | × | × | ||||||||
Heisler et al. 2020 [24] | USA | 2 | 1 | 263 | 81.8 | Clinics: five US academic medical centers | 54.7 (13.8) | 9.8 (11.9) | x | × | × | × | × | ||||||||
Hitchon et al. 2020 [25] | USA | 1 | 1 | 150 | 84.7 | Clinic & Community: Arthritis Center in Winnipeg | 59.8 (11.7) | 41.7 (14.9)a | × | × | |||||||||||
Hwang et al. 2020 [26] | USA | 2 | 2 | 119 | 69.0 M | Clinic: University of Texas Health Science Center | 50.9 (14.77) | 25.5 (13.3) | × | × | × | × | × | × | |||||||
Katz et al. 2020 [27] | USA | 2 | 1 | 3848 | 83.1 | Registry: The National Databank for Rheumatic Diseases (FORWARD) registry | 64.9 (12.0) | 20.8 (12.7) | × | ||||||||||||
Liew et al. 2020 [28] | USA | 2 | 2 | 203 | 66.0 M | Clinic: University of California, San Francisco | 46.4 (12.5) | 22.9 (12.4) | × | ||||||||||||
Prodinger et al. 2020 [29] | Ger UK | 1 | 1 | 180 535 | 91.4 74.2 | Clinic: sample from Germany Clinic: Sample From UK | 49.0 (13.8) 68.3 (10.0) | 13.5 (12.2) 19.8 (13.0) | × | ||||||||||||
USA | 1 | 1 | 348 | 81.0 | Clinics: Johns Hopkins, The Hospital for Special Surgery, University of Alabama | 57.0 (14.0) | 14.0 (11.0) | × | × | × | × | × | |||||||||
NL | 1 | 1 | 2029 1554 | 69.0 69.0 | Clinic: Outpatient patients from Reade and Leuven, used Pain Interference Clinic: Outpatient patients from Reade and Leuven, used Pain behavior | 59.0 (13.0) 59.0 (12.0) | 1–12 months 2% 1–2 years 7% 2–5 years 16% > 5 years 75%c 1–12 months 2% 1–2 years 6% 2–5 years 15% > 5 years 76%c | × | × | ||||||||||||
Izadi et al. 2019 [34] | USA | 2 | 1 | 595 | 83.0 | Clinic: University of California, San Francisco | 56.8 (15.3) | × | |||||||||||||
Mahmoud et al. 2019 [35] | EG | 1 | 1 | 120 | 94.0 | Clinic: Outpatient clinic Cairo University | 41.5 (11.1) | 6.3 (7.3) | × | × | × | × | × | × | |||||||
Wohlfahrt et al. 2019 [36] | USA | 2 | 1 | 156 | 82.1 | Clinics: five US academic medical centers | 54.6 (13.6) | 10.0 (12.6) | x | × | × | × | × | × | × | × | |||||
Alleva et al. 2018 [37] | UK/NL | 3 | 1 | 84 | 100.0 | Community: Female RA population | 44.8 (12.5) | 11.3 (10.9) | × | × | |||||||||||
USA | 1 | 1 | 200 52 32 | 84.0 87.0 72.0 | Community: Creakyjoints.org Clinic: Johns Hopkins Arthritis Centre patients Clinics: Johns Hopkins, Hospital for Special Surgery, University of Alabama | 51.0 (12.0) 53.0 (14.0) 54.0 (13.0) | 10.0 (10.0) 15.0 (11.0) 13.0 (10.0) | × | × | × | × | × | × | ||||||||
Katz et al. 2018 [39] | USA | 3 | 1 | 96 | 84.0 | Clinic: University of California, San Francisco | 54.8 (13.4) | 14.8 (12.3) | × | × | |||||||||||
Mollard et al. 2018 [40] | USA | 4 | 1 | 63 | Clinic: Rheumatology and Arthritis Investigational Network Database | > 18 yearsd | × | ||||||||||||||
Bacalao et al. 2017 [41] | USA | 2 | 1 | 119 | 91.0 | Clinic: Northwestern University Feinberg School of Medicine | 57.0(21.0–77.0)b | 11.0(0–52)b | × | × | × | × | |||||||||
Katz et al. 2017 [42] | USA | 2 | 1 | 4346 | 83.0 | Registry: The National Databank for Rheumatic Diseases (FORWARD) registry | 64.0 (12.0) | 20.0 (13.0) | × | ||||||||||||
Wahl et al. 2017 [43] | USA | 2 | 1 | 326 | 81.6 | Clinic: University of California, San Francisco | 59.0 (14.0) | 12.0(5.0–22.0)b | × | ||||||||||||
USA | 2 | 1 | 521 | 81.0 | Registry: The Arthtritis Rheumatism and Aging Medical Information System (ARAMIS) registry | 88% ≥ 50c | × | × | × | ||||||||||||
Bjorner et al. 2014 [48] | USA | 4 | 1 | 223 | 35.0 M | Community: contacted RA patients | 56.0 (10.0) | × | × | × | |||||||||||
NL | 2 | 1 | 690 557 | 63.6 52.6 | Registry: The Dutch Rheumatoid Arthritis Monitoring (DREAM) Community: contacted US RA sample | 56.8 (11.8) 56.7 (10.9) | × | ||||||||||||||
USA | 2 | 1 | 451 | 81 | Registry: The Arthtritis Rheumatism and Aging Medical Informatio System (ARAMIS) registry | 65 | × | × | × | ||||||||||||
N articles axSpA patients | 1 | 0 | 2 | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | ||||||||
N studies axSpA patients | 1 | 0 | 2 | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | ||||||||
N articles RA patients | 2 | 3 | 20 | 15 | 18 | 3 | 2 | 8 | 1 | 6 | 8 | 13 | 1 | ||||||||
N studies RA patients | 2 | 3 | 12 | 12 | 15 | 2 | 2 | 6 | 1 | 4 | 6 | 11 | 1 |
PROMIS measure used | N of articles | N of studies | Publication year | Reference of articles |
---|---|---|---|---|
PROMIS Global Health (GH) | 3 | 3 | ||
PROMIS Global Health Short Formc | 1 | 1 | 2021 | [24] |
PROMIS Global Health Short Form version 1.1a | 1 | 1 | 2021 | [26] |
PROMIS Global Health version 1.1a | 1 | 1 | 2019 | [36] |
PROMIS-29 | 3 | 3 | ||
PROMIS Adult profile-29ac | 2 | 2 | 2019, 2017 | |
PROMIS Adult profile-29 (v2.0)a | 1 | 1 | 2020 | [31] |
PROMIS Physical Function | 22 | 14 | ||
PROMIS Physical Functionc | 1 | 1 | 2021 | [46] |
PROMIS physical Function Item Bankc | 1 | 1 | 2014 | [49] |
PROMIS CAT Physical Functionc | 5 | 4 | 2022, 2020, 2020, 2020, 2017 | |
PROMIS CAT Physical Function 10-item | 1 | 1 | 2014 | [50] |
PROMIS CAT Physical Function (v.1.0) | 1 | 1 | 2020 | [21] |
PROMIS Physical Function 4-items Short Form | 1 | 1 | 2020 | [29] |
PROMIS Physical Function 6-items Short Form | 1 | 1 | 2020 | [29] |
PROMIS Physical Function 8-items Short Form | 2 | 2 | 2014, 2011 | |
PROMIS Physical Function 10-items Short form | 3 | 3 | 2020, 2015, 2011 | |
PROMIS Physical Function 10a Short Form | 3 | 3 | 2019, 2019, 2017 | |
PROMIS Physical Function 12a Short Form (v1.0)b | 1 | 1 | 2020 | [26] |
PROMIS Physical Function 20-items Short Form | 4 | 3 | 2020, 2016, 2011, 2015 | |
PROMIS Physical Function 20a Short Form | 1 | 1 | 2019 | [30] |
PROMIS Physical Function 20a Short Form (v 1.0)a | 2 | 2 | 2020, 2020 | |
PROMIS fatigue | 16 | 13 | ||
PROMIS Item Bank Fatiguec | 1 | 1 | 2021 | [17] |
PROMIS CAT Fatiguec | 5 | 4 | 2020, 2020, 2020, 2019, 2017 | |
PROMIS CAT Fatigue (v.1.0) | 1 | 1 | 2020 | [21] |
PROMIS Fatigue Short Form (version 1) | 2 | 2 | 2020, 2016 | |
PROMIS Fatigue 4a Short Form | 1 | 1 | 2019 | [35] |
PROMIS Fatigue 7a Short Form | 2 | 2 | 2019, 2018 | |
PROMIS Fatigue 7a Short Form (v 1.0) | 4 | 4 | 2020, 2020, 2018, 2021 | |
PROMIS Fatigue 8-items Short Form | 1 | 1 | 2014 | [48] |
PROMIS Fatigue 8a Short Form | 1 | 1 | 2019 | [30] |
PROMIS Fatigue 8a Short Form (v 1.0) | 2 | 2 | 2020, 2018 | |
PROMIS Pain Interference [Pain IF) | 20 | 17 | ||
PROMIS Pain Interference Item Bankc | 4 | 4 | 2021, 2021, 2021, 2016 | |
PROMIS Pain Interference Item Bank (v 1.1)a | 2 | 1 | 2019, 2020 | |
PROMIS CAT Pain Interferencec | 7 | 6 | 2022, 2020, 2020, 2020, 2020, 2019, 2017 | |
PROMIS CAT Pain Interference (v1.0) | 1 | 1 | 2020 | [21] |
PROMIS Pain Interference 4a Short Form | 1 | 1 | 2019 | [35] |
PROMIS Pain Interference 4-items Short Form | 1 | 1 | 2020 | [27] |
PROMIS Pain Interference 8-items Short form | 1 | 1 | 2018 | [39] |
PROMIS Pain Interference 8a Short Form | 1 | 1 | 2019 | [30] |
PROMIS Pain Interference 8a Short Form (v 1.0)a | 3 | 3 | 2020, 2020, 2020 | |
PROMIS Pain Interference 6b-item Short Form (version 1.1)a | 1 | 1 | 2021 | [46] |
PROMIS Pain Behavior (Pain BH) | 3 | 2 | ||
PROMIS Pain Behavior Item Bank (v.1.1)a | 2 | 1 | 2019, 2020 | |
PROMIS CAT Pain Behaviorc | 1 | 1 | 2019 | [36] |
PROMIS Pain Intensity (Pain IT) | 3 | 3 | ||
PROMIS Pain Intensity Short Form (v1.0) | 1 | 1 | 2020 | [26] |
PROMIS Pain Intensity 3a Short Form | 2 | 2 | 2019, 2019 | |
PROMIS Sleep Disturbance/Sleep-Related Impairment | 9 | 7 | ||
PROMIS Sleep Disturbance Item Bank (v1.0) | 1 | 1 | 2021 | [16] |
PROMIS CAT Sleep Disturbancec | 5 | 4 | 2020, 2020, 2020, 2020, 2019 | |
PROMIS CAT Sleep Disturbance (v.1.0) | 1 | 1 | 2020 | [21] |
PROMIS CAT Sleep-Related Impairmentc | 1 | 1 | 2019 | [36] |
PROMIS CAT Sleep Interferenceb | 2 | 2 | 2022, 2020 | |
PROMIS Sleep Disturbance 4a Short Form | 1 | 1 | 2019 | [35] |
PROMIS Sleep Disturbance 4a Short Form (v.1.0) | 1 | 1 | 2020 | [21] |
PROMIS Satisfaction with Social Roles and Activities | 1 | 1 | [20] | |
PROMIS CAT Satisfaction with Social Rolesc | 1 | 1 | 2020 | [20] |
PROMIS Ability to Participate in Social roles and Activities (APS) | 6 | 4 | ||
PROMIS CAT Participation in Social Roles and Activitiesb | 1 | 1 | 2020 | [20] |
PROMIS CAT Ability to Participate in Social Participationb | 1 | 1 | 2020 | [22] |
PROMIS CAT Ability to Participate in Social Roles (v2.0)b | 1 | 1 | 2020 | [21] |
PROMIS Ability to Participate in Social Roles and Activities 8a Short Form (v.2.0) | 3 | 3 | 2021, 2020, 2020 | |
PROMIS Participation in Social Roles and Activities 8a Short Form | 1 | 1 | 2019 | [30] |
PROMIS anxiety/anger | 9 | 7 | ||
PROMIS Anxiety Short Formb | 1 | 1 | 2018 | [37] |
PROMIS Anxiety Short Form 4a | 1 | 1 | 2019 | [35] |
PROMIS Anxiety 4a Short Form (v.1.0)a | 1 | 1 | 2020 | [21] |
PROMIS Anxiety Short Form (6-items) | 1 | 1 | 2020 | [28] |
PROMIS Anxiety 8a Short Form | 1 | 1 | 2020 | [25] |
PROMIS CAT Anxietyc | 4 | 3 | 2020, 2020, 2020, 2019 | |
PROMIS CAT Anxiety (v1.0)c | 1 | 1 | 2020 | [21] |
PROMIS CAT Angerc | 1 | 1 | 2020 | [20] |
PROMIS Depression | 14 | 12 | ||
PROMIS Item Bank Depressionc | 1 | 1 | 2014 | [48] |
PROMIS Emotional Distress-Depression Item Bankc | 1 | 1 | 2011 | [52] |
PROMIS CAT Depressionc | 5 | 4 | 2020, 2020, 2020, 2019, 2017 | |
PROMIS CAT Depression (v1.0)c | 1 | 1 | 2020 | [21] |
PROMIS Depression Short Formc | 1 | 1 | 2018 | [37] |
PROMIS Depression 4a Short Form | 1 | 1 | 2019 | [35] |
PROMIS Depression 8a Short Form | 2 | 2 | 2020, 2019 | |
PROMIS Depression 8a Short Form (v.1.0) | 1 | 1 | 2020 | [21] |
PROMIS Emotional Distress-Depression Short Form (v1.0) | 1 | 1 | 2020 | [26] |
PROMIS Self-Efficacy Managing Symptoms (SEMS) | 1 | 1 | [40] | |
PROMIS Self-Efficacy Managing Symptoms (P-SEMS)c | 1 | 1 | 2018 | [40] |
Study and articles within the study reporting T-scores | Articles or cohorts within the study Reporting PROMIS outcome | GH | P-29 | Physical Function | Fatigue | Pain IF | Pain BH | Pain IT | Sleep Disturbance/Sleep-Related Impairmenti | Satisfaction with social roles and actitvities | APS | Anxiety | Depression |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gavigan et al. 2022 [55] | 36.6(6.4) | 65.8 (6.2) | 60.6 (8.2) | ||||||||||
Cano-García et al. 2021 [18] | RA population[18] axSpA population [18] | RA: 26.2 (7.8) axSpA: 26.9 (8.2) | |||||||||||
Craig et al. cohort 1 [21] Craig et al. cohort 2 [21] | Cohort 1:43.7 (8.9) Cohort 2: 40.5 (9.7) | Cohort 1: 53.6 (10.1) Cohort 2: 55.0 (10.7) | Cohort 1: 53.5 (9.3) Cohort 2: 57.6 (10.1) | Cohort 1: 51.5 (9.7) Cohort 2: 52.0 (10.5) | Cohort 1: 50.5 (8.9) Cohort 2: 47.2 (10.2) | Cohort 1: 50.5 (8.3) Cohort 2: 51.1 (9.7) | Cohort 1: 48.7 (8.8) Cohort 2: 49.0 (9.4) | ||||||
Gavigan et al. 2020b [23] | 37.8 (34.0–40.8) | 63.0 (58.7–67.9) | 63.3 (60.3–66.9) | 59.2 (54.3–63.0) | |||||||||
Heisler et al. 2020 [24] | m | 53.6 (8.9) | 50.9 (9.1) | ||||||||||
Hitchon et al. 2020 [25] | ≥ 60 h 24.0% | ≥ 60 h 22.7% | |||||||||||
Hwang et al. 2020 [26] | 45.6 (8.9) | 46.6 (9.8) | 51.1 (10.5) | 52.2 (9.9) | 45.7 (8.9) | 45.3 (8.5) | |||||||
Katz et al. 2020 [27] | 56.3 (95) | ||||||||||||
Liew et al. 2020 [28] | 54.0 (9.0) | ||||||||||||
Bingham et al. 2019 [30] | m | 38.7 (9.4) | 58.0 (11.6)c 58.0 (11.5)d 58.6 (11.6)e | 53.9 (10.0) | 44.8 (10.3)d | 52.9 (10.1) | 51.5 (10.5)§§ | ||||||
Crins et al. 2019 [32] | 53.6 (9.8) | 56.7 (5.1) | |||||||||||
Izadi et al. 2019 [34] | 40.1 (10.7) | ||||||||||||
Mahmoud et al. 2019 [35] | 37.6 (6.9) | 59.3 (5.9) | 61.1 (5.5) | 53.6 (5.5) | 54.6 (3.7) | 59.9 (6.0) | 57.7 (8.3) | ||||||
Wohlfahrt et al. 2019 [36] | 41.4 (7.3)k 48.0 (8.2)l | 56.8 (8.6)c | 60.6 (7.3) | 59.2 (4.7) | 51.5 (6.0) | 55.2 (9.8)j 55.2 (8.5) | 54.3 (8.8) | 50.8 (9.7) | |||||
Bartlett et al. cohort 1 [38] | Cohort 1: 54.8 (13.6)d 54.6 (11.2)e | ||||||||||||
Bartlett et al. cohort 2 [38] | Cohort 2: 65.6 (8.1)d 66.0 (7.8)e | ||||||||||||
Bartlett et al. cohort 3 [38] | Cohort 3: 53.2 (9.9)d 55.3 (10.3)e | ||||||||||||
Katz et al. 2018 [39] | 59.3 (6.7) | 60.9 (7.3) | |||||||||||
Bacalao et al. 2017 [41] | 42.3 (5.9) | 56.4 (9.2) | 57.6 (7.5) | 51.4 (8.4) | |||||||||
Katz et al. 2017 [42] | m | 42.0 (9.1) | 53.6 (11.0) | 56.4 (9.4) | 51.2 (9.3) | 48.9 (9.7) | 48.3 (9.2) | 47.8 (8.7) | |||||
Wahl et al. 2017 [43] | 40.2 (10.5) | ||||||||||||
Article 1: Askew et al. 2016 [44]a Article 2: Cella et al. 2015 [45] Article 3: Beaumont et al. 2021 [46] Article 4: Schalet et al. 2016 [47]a | Article 3: 40.7 (9.0) Article 4: 40.7 (39.9–41.5) | Article 2: 53.8 (8.8)b Article 3: 53.7 (8.8)g | Article 1: 55.3 (54.6–56.0) Article 2: 55.2 (8.6) | ||||||||||
Fries et al. 2011 [53] | 33.9 (22.0)f 30.6 (21.0)g |